In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the ...

In a review of 182 cancer studies, authors failed to report outcome data by sex in 90% of cases, even though men develop ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points.

Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals ...

Talus Bioscience, a technology-enabled therapeutics company, today announced new preclinical data from programs targeting transcription factors in chordoma, non-small cell lung cancer, and advanced ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Cancer completely disappeared from two-thirds of 24 patients treated with a combination of the antibody petosemtamab and ...

Numerous studies conducted by researchers at Dana-Farber Cancer Institute report progress for cancers including head and neck ...

A rare cell type in the lungs is essential to survival from the COVID-19 virus, a new study shows.

Through its Precision Care Companion, McKesson wants to help oncologists bring personalized medicine to their patients ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...